These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 11119419)

  • 1. Preservation of graft-versus-infection effects after suicide gene therapy for prevention of graft-versus-host disease.
    Cohen JL; Saron MF; Boyer O; Thomas-Vaslin V; Bellier B; Lejeune L; Charlotte F; Klatzmann D
    Hum Gene Ther; 2000 Dec; 11(18):2473-81. PubMed ID: 11119419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunological defects after suicide gene therapy of experimental graft-versus-host disease.
    Cohen JL; Lacroix-Desmazes S; Charlotte F; Lejeune L; Martin PJ; Klatzmann D; Boyer O
    Hum Gene Ther; 1999 Nov; 10(16):2701-7. PubMed ID: 10566898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of combined cytostatic cyclosporin A and cytolytic suicide gene therapy on the prevention of experimental graft-versus-host disease.
    Maury S; Litvinova E; Boyer O; Benard L; Bruel S; Klatzmann D; Cohen JL
    Gene Ther; 2002 Feb; 9(3):201-7. PubMed ID: 11859423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution.
    Gendelman M; Yassai M; Tivol E; Krueger A; Gorski J; Drobyski WR
    Biol Blood Marrow Transplant; 2003 Dec; 9(12):742-52. PubMed ID: 14677113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Graft-versus-leukemia effect after suicide-gene-mediated control of graft-versus-host disease.
    Litvinova E; Maury S; Boyer O; Bruel S; Benard L; Boisserie G; Klatzmann D; Cohen JL
    Blood; 2002 Sep; 100(6):2020-5. PubMed ID: 12200361
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of graft-versus-host disease. Use of a T cell-controlled suicide gene.
    Helene M; Lake-Bullock V; Bryson JS; Jennings CD; Kaplan AM
    J Immunol; 1997 Jun; 158(11):5079-82. PubMed ID: 9164920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetically engineered T-cells expressing a ganciclovir-sensitive HSV-tk suicide gene for the prevention of GvHD.
    Mailly L; Leboeuf C; Tiberghien P; Baumert T; Robinet E
    Curr Opin Investig Drugs; 2010 May; 11(5):559-70. PubMed ID: 20419602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suicide gene therapy for graft-versus-host disease.
    Georgoudaki AM; Sutlu T; Alici E
    Immunotherapy; 2010 Jul; 2(4):521-37. PubMed ID: 20636006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suicide gene therapy of graft-versus-host disease: immune reconstitution with transplanted mature T cells.
    Cohen JL; Boyer O; Klatzmann D
    Blood; 2001 Oct; 98(7):2071-6. PubMed ID: 11567992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of TK-cells in haploidentical hematopoietic stem cell transplantation.
    Oliveira G; Greco R; Lupo-Stanghellini MT; Vago L; Bonini C
    Curr Opin Hematol; 2012 Nov; 19(6):427-33. PubMed ID: 22918402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Suicide-gene-Transduced donor T-cells for controlled graft-versus-host disease and graft-versus-tumor.
    Ciceri F; Bordignon C
    Int J Hematol; 2002 Nov; 76(4):305-9. PubMed ID: 12463592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Donor lymphocytes expressing the herpes simplex virus thymidine kinase suicide gene: detailed immunological function following add-back after haplo-identical transplantation.
    Hashimoto H; Kitano S; Yamagata S; Miyagi Maeshima A; Ueda R; Ito A; Tada K; Fuji S; Yamashita T; Tomura D; Nukaya I; Mineno J; Fukuda T; Mori S; Takaue Y; Heike Y
    Cytotherapy; 2015 Dec; 17(12):1820-30. PubMed ID: 26452983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Production and first-in-man use of T cells engineered to express a HSVTK-CD34 sort-suicide gene.
    Zhan H; Gilmour K; Chan L; Farzaneh F; McNicol AM; Xu JH; Adams S; Fehse B; Veys P; Thrasher A; Gaspar H; Qasim W
    PLoS One; 2013; 8(10):e77106. PubMed ID: 24204746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modulation of GvHD by suicide-gene transduced donor T lymphocytes: clinical applications in mismatched transplantation.
    Ciceri F; Bonini C; Gallo-Stampino C; Bordignon C
    Cytotherapy; 2005; 7(2):144-9. PubMed ID: 16040393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes.
    Bondanza A; Valtolina V; Magnani Z; Ponzoni M; Fleischhauer K; Bonyhadi M; Traversari C; Sanvito F; Toma S; Radrizzani M; La Seta-Catamancio S; Ciceri F; Bordignon C; Bonini C
    Blood; 2006 Mar; 107(5):1828-36. PubMed ID: 16293601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Experimental study of the inhibiting effect of the lentiviral vector mediated herpes simplex virus-thymidine kinase/ganciclovir on GVHD].
    Xu KL; Zhu F; Du B; Gao F; Cheng H; Pan XY
    Zhonghua Xue Ye Xue Za Zhi; 2007 May; 28(5):303-7. PubMed ID: 17877157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced graft-versus-host disease-inducing capacity of T cells after activation, culturing, and magnetic cell sorting selection in an allogeneic bone marrow transplantation model in rats.
    Weijtens M; van Spronsen A; Hagenbeek A; Braakman E; Martens A
    Hum Gene Ther; 2002 Jan; 13(2):187-98. PubMed ID: 11812276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient control of a virus-induced immunopathology by genetic immunosuppression.
    Boyer O; Cohen JL; Bellier B; Thomas-Vaslin V; Klatzmann D; Saron MF
    Gene Ther; 2000 Sep; 7(18):1536-42. PubMed ID: 11021591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylaxis of graft-versus-host disease by lentiviral-mediated expression of herpes simplex virus-thymidine kinase and ganciclovir treatment.
    Xu K; Zhu F; Du B; Gao F; Cheng H; Pan X
    Transplant Proc; 2008 Oct; 40(8):2665-9. PubMed ID: 18929831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.